SEC Form 4 · accession 0001209191-18-030361
Intellia Therapeutics, Inc. · NTLA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John M. Leonard
Officer — President and CEO · Director
Period of report
May 14, 2018
Accepted (ET)
May 15, 2018 · 8:43 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001652130
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | May 14, 2018 | S | 8,400 | $24.00 | D | 0 | I | By Trust |
| Common StockF3 | holding | — | — | — | 467,352 | D | ||
| Common StockF4 | holding | — | — | — | 58,415 | I | By Trust |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1The shares were sold pursuant to a Rule 10b5-1 trading plan. All shares were sold at $24.00.
- F2Shares sold by the John Leonard Defined Benefit Pension Plan and Trust.
- F3Includes 513 and 431 shares acquired under the Intellia Therapeutics, Inc. 2016 Employee Stock Purchase Plan on June 30, 2017 and December 31, 2017, respectively.
- F4Shares held by the John M. Leonard 2015 Irrevocable Trust.